Sandbox leucocytosis: Difference between revisions
Aditya Ganti (talk | contribs) No edit summary |
Aditya Ganti (talk | contribs) No edit summary |
||
Line 458: | Line 458: | ||
{| | {| | ||
|- | |- | ||
! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Normal variant oral lesions | ! colspan="2" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Normal variant oral lesions | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 466: | Line 465: | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoedema | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoedema | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 474: | Line 472: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Fordyce granules | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Fordyce granules | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 482: | Line 479: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign Oral lesions | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign Oral lesions | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 490: | Line 486: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pyogenic granuloma | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Pyogenic granuloma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 498: | Line 493: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral ossifying fibroma | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral ossifying fibroma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 506: | Line 500: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Granular cell tumor | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Granular cell tumor | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 514: | Line 507: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral giant cell granuloma | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral giant cell granuloma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 522: | Line 514: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral hemangioma | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral hemangioma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 530: | Line 521: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Palisaded encapsulated neuroma | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Palisaded encapsulated neuroma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 538: | Line 528: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Neurofibroma | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Neurofibroma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 562: | Line 551: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pre-malignant oral lesions | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pre-malignant oral lesions | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 634: | Line 622: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant oral lesions | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant oral lesions | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 644: | Line 631: | ||
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Epithelial tissue origin | * Epithelial tissue origin | ||
| | |Squamous cell carcinoma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 651: | Line 638: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| | |Basal cell carcinoma | ||
| | | | ||
| | | | ||
Line 658: | Line 645: | ||
| | | | ||
|- | |- | ||
| | |Verrucous crcinoma | ||
| | | | ||
| | | | ||
Line 665: | Line 652: | ||
| | | | ||
|- | |- | ||
| | |Spindle cell carcinoma | ||
| | | | ||
| | | | ||
Line 672: | Line 659: | ||
| | | | ||
|- | |- | ||
| | |Adenoid squamous cell carcinoma | ||
| | | | ||
| | | | ||
Line 679: | Line 666: | ||
| | | | ||
|- | |- | ||
| | |Lymphoepithelioma and transitional cell carcinoma | ||
| | | | ||
| | | | ||
Line 686: | Line 673: | ||
| | | | ||
|- | |- | ||
| | |Malignant melanoma | ||
| | | | ||
| | | |
Revision as of 16:49, 23 January 2019
Disease | Presentation | Risk Factors | Diagnosis | Affected Organ Systems | Important features | Picture |
---|---|---|---|---|---|---|
Diseases predominantly affecting the oral cavity | ||||||
Oral Candidiasis |
|
|
|
Localized candidiasis
Invasive candidasis |
|
|
Herpes simplex oral lesions |
|
|
|
|
||
Aphthous ulcers |
|
|
|
|
|
|
Squamous cell carcinoma |
|
|
||||
Leukoplakia |
|
|
|
|
||
Melanoma |
|
|
|
|
||
Fordyce spots |
|
|
|
|
||
Burning mouth syndrome |
|
|
||||
Torus palatinus |
|
|||||
Diseases involving oral cavity and other organ systems | ||||||
Behcet's disease |
|
|
|
|||
Crohn's disease |
|
|
|
|||
Agranulocytosis |
|
|
||||
Syphilis |
|
|
|
|||
Coxsackie virus |
|
|
||||
Chicken pox |
|
|
|
|
||
Measles |
|
|
|
|
Normal variant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | ||
---|---|---|---|---|---|---|
Leukoedema | ||||||
Fordyce granules | ||||||
Benign Oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | ||
Pyogenic granuloma | ||||||
Peripheral ossifying fibroma | ||||||
Granular cell tumor | ||||||
Peripheral giant cell granuloma | ||||||
Oral hemangioma | ||||||
Palisaded encapsulated neuroma | ||||||
Neurofibroma | ||||||
Neodymium-doped yttrium alluminium garnet | ||||||
Pigmented lesions | ||||||
Pre-malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | ||
Leukoplakia | ||||||
Oral proliferative verrucous leukoplakia | ||||||
Erythroplakia | ||||||
Oral submucus fibrosis | ||||||
Oral lichen planus and lichenoid lesions | ||||||
Oral discoid lupus erythmatosus | ||||||
Oral chronic graft vs host disease | ||||||
Actinic chelitis | ||||||
Malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | ||
|
Squamous cell carcinoma | |||||
Basal cell carcinoma | ||||||
Verrucous crcinoma | ||||||
Spindle cell carcinoma | ||||||
Adenoid squamous cell carcinoma | ||||||
Lymphoepithelioma and transitional cell carcinoma | ||||||
Malignant melanoma | ||||||
|
||||||
|
||||||
|
||||||
|
||||||
|
Type of cancer | Subtype | Epidemiology | Localization | Clinical features | Diagnostic procedures |
---|---|---|---|---|---|
Squamous cell carcinoma
|
Verrucous carcinoma |
|
|
|
Biopsy shows:
Thickened club-shaped papillae and blunt stromal invaginations of well-differentiated squamous epithelium with marked keratinization |
Lymphoepithelial carcinoma | 0.8-2% of all oral or oropharyngeal cancers |
|
|
Biopsy chows:
| |
Epithelial precursor lesions | --- | --- | Seen in the entire digestive tract |
|
Biopsy shows:
|
Proliferative verrucous leukoplakia and precancerous conditions | --- |
|
|
An aggressive form of oral leukoplakia with considerable morbidity and
strong predilection to malignant transformation |
Biopsy shows:
|
Papillomas | Squamous cell papilloma and |
|
Any oral site may be affected mostly:
|
Soft, pedunculated lesions formed by a cluster of finger-like fronds or a sessile, dome-shaped lesion with a nodular, papillary or verrucous surface | Biopsy shows:
|
Condyloma acuminatum | 2nd and 5th decade with a peak in teenagers and young adults |
|
Biopsy shows:
Several sessile, cauliflower-like swellings forming a cluster | ||
Focal epithelial hyperplasia | Disease of children, adolescents and young adults |
|
|
Biopsy shows:
| |
Granular cell tumor | --- |
|
|
|
Biopsy shows:
|
Keratoacanthoma | --- |
whites
men as in women |
|
|
Biopsy shows:
|
Papillary hyperplasia | --- | Affects all age groups | Palate | Asymptomatic nodular or papillary mucosal lesion | Biopsy shows:
|
Median rhomboid glossitis | --- | --- | Dorsum of the tongue at the junction of the anterior two thirds
and posterior third |
Forms a patch of papillary atrophy in the region of the
embryological foramen caecum |
Biopsy shows:
|
Salivary gland tumors | Acinic cell carcinoma |
|
Tumors usually
form non-descript swellings |
Biopsy shows:
| |
Mucoepidermoid carcinoma |
|
|
|
Low power microscopy shows low-grade tumor with both cystic and solid areas and an inflamed, fibrous stroma | |
Adenoid cystic carcinoma |
|
|
Predominantly solid variant shows peri- and intraneural invasion | ||
Epithelial-myoepithelial
carcinoma |
--- | --- | --- | --- | |
Clear cell carcinoma,
NOS |
--- | --- | --- | ||
Basal cell | Rare in minor glands | Asymptomatic, smooth or lobulated sub-mucosal masses | Microscopically similar to basal
cell adenocarcinomas of the major gland | ||
Cystadenocarcinoma | 32% developed in the minor glands |
|
Slow growing and painless but
some palatal tumors may erode the underlying bone causing sinonasal complex |
--- | |
Salivary duct carcinoma |
|
|
Tumors formed painless swellings but many in the palate can be painful and ulcerated or fungated with metastases to regional lymph nodes | The range of
microscopical appearances is similar to that seen in the major glands | |
Salivary gland adenomas | Pleomorphic adenoma | 40-70% of minor gland tumors |
|
Painless, slow growing, submucosal masses, but when | Biopsy shows cellular, and hyaline or plasmacytoid cell |
Myoepithelioma | 42% of minor gland tumors |
|
--- | --- | |
Basal cell adenoma | 20% of minor gland tumors | --- | They are histologically
similar to those in major glands. | ||
Cystadenoma | 7% of benign minor gland tumors | --- | --- | ||
Kaposi sarcoma | --- |
|
|
Biopsy of all 4 types show:
| |
Lymphangioma | --- |
|
Tongue |
|
Biopsy shows:
|
Ectomesenchymal chondromyxoid
tumour of the anterior tongue |
--- |
|
--- | Asymptomatic, slow growing solitary nodule in the anterior dorsal tongue | Biopsy shows:
|
Focal oral mucinosis (FOM) | --- |
|
Asymptomatic fibrous or cystic-like lesion | Histopathology is characterized by:
| |
Congenital granular cell epuli | --- |
|
Solitary, somewhat pedunculated fibroma-like lesion attached to the alveolar
ridge near the midline |
||
Hematolymphoid tumors | Non-Hodgkin lymphoma | Second most common cancer of the oral cavity |
|
NHL of the lip presents with:
|
Biopsy shows:
|
Langerhans cell histiocytosis | --- |
and |
Common oral symptoms
include:
|
Biopsy shows ovoid Langerhans cells
with deeply grooved nuclei, thin nuclear membranes and abundant eosinophilic cytoplasm | |
Hodgkin lymphoma | --- |
|
Most patients present with localized disease (stage I/II), with
|
--- | |
Extramedullary myeloid
sarcoma |
--- | Isolated tumor-forming intraoral mass | Biopsy shows an Indian-file pattern of infiltration | ||
Follicular dendritic cell
sarcoma / tumour |
|
|
The patients usually
present with a painless mass |
Biopsy usually exhibits
borders and comprises:
| |
Mucosal malignant melanoma | --- |
|
80% arise:
Others:
|
|
|